CEBPA and acute myeloid leukemia: For instance, patients with AML harboring NPM1 mutation and FLT3 wildtype or FLT3-ITD with low allelic ratio, AML with biallelic CEBPA mutation, or with core-binding factor AML are categorized within the favorable risk group and may require only induction chemotherapy followed by consolidation chemotherapy [1, 2].